Phenotypes Associated with This Genotype

Genotype
MGI:5752239

• Allelic Composition: Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh; Nras^tm1.1Nesh/Nras^tm1.1Nesh; Stk11^tm1.1Rdp/Stk11^tm1.1Rdp; Tg(Tyr-cre/ERT2)13Bos/0
• Genetic Background: B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nras^tm1.1Nesh Cdkn2a^tm2.1Nesh Stk11^tm1.1Rdp

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

integument

increased cutaneous melanoma incidence ( J:220627 )

• mice treated with 4-hydroxytamoxifen (4-OHT) neonatally or in adulthood exhibit enhanced nevus formation

• mice treated with 4-OHT neonatally develop melanoma with 85% penetrance and a median latency of 22.1 weeks

neoplasm

increased cutaneous melanoma incidence ( J:220627 )

• mice treated with 4-hydroxytamoxifen (4-OHT) neonatally or in adulthood exhibit enhanced nevus formation

• mice treated with 4-OHT neonatally develop melanoma with 85% penetrance and a median latency of 22.1 weeks

increased metastatic potential ( J:220627 )

• 36% of mice treated with 4-OHT neonatally that develop melanoma show macrometastatic spread to lymph nodes, lung, spleen and/or liver

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
skin melanoma		DOID:8923	OMIM:608035 OMIM:612263	J:220627